Medicine and Dentistry
Protein
100%
Ring Finger
100%
Patient
83%
Inpatient
83%
Cyclophosphamide
83%
Diseases
66%
Peptide
50%
Low Drug Dose
50%
Solid Malignant Neoplasm
50%
Immunocompetent Cell
33%
Cell Therapy
33%
Dendritic Cell
33%
Interferon
16%
Neoplasm
16%
Combination Therapy
16%
Therapeutic Procedure
16%
Adverse Event
16%
Tumor Cell
16%
Lymphocyte
16%
Regulatory T Cell
16%
Immune Response
16%
Combined Therapy
16%
Tumor Antigen
16%
Interleukin 2
16%
Specific Tumor
16%
Progressive Disease
16%
Immunotherapy
16%
HLA-A
16%
Immunology and Microbiology
Ring Finger
100%
Cyclophosphamide
83%
Regulatory T Cell
50%
Solid
50%
Low Drug Dose
50%
Immunocompetent Cell
33%
Cytotoxic T-Cell
33%
Dendritic Cell
33%
Interferon Type I
16%
Immune Response
16%
Time
16%
Tumor Cell
16%
Interleukin 2
16%
Immunotherapy
16%
Lymphocyte
16%
Tumor-Associated Antigen
16%
HLA A24 Antigen
16%
Pharmacology, Toxicology and Pharmaceutical Science
Protein
100%
Cyclophosphamide
83%
Diseases
66%
Peptide
50%
Solid Malignant Neoplasm
50%
Clinical Trial
33%
Adverse Event
16%
Neoplasm
16%
Interferon
16%
Immunotherapy
16%
Tumor Antigen
16%
Interleukin 2
16%
Tolerability
16%